Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $256.75M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.47M
Average 7.51M
OCGN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Ocugen, Inc.NASDAQ: OCGN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$17.27M, compared with -$13.53M a year earlier. Trailing-twelve-month EBITDA was -$64.18M.
Context
- EBITDA amounted to 1365.7% of revenue in FY2025, up 81.2 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$55.67M (+7.6%) for the fiscal year ending Dec 2026, a step up from the -15.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$17.27M-5.4% QoQ
- Last fiscal yearDec 2025
- -$60.27M-15.7% YoY
- LTMMar 2026
- -$64.18M-19.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -27.6% | -2.2% | +25.5 pp |
| 1 year | -15.7% | +7.6% | +23.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (60.27M) USD
- Year-over-year change
- -15.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (60.27M) | -15.7% |
| FY2024 | 2024-12-31 | (52.09M) | +16.5% |
| FY2023 | 2023-12-31 | (62.37M) | +27.7% |
| FY2022 | 2022-12-31 | (86.32M) | -48.6% |
| FY2021 | 2021-12-31 | (58.11M) | — |
EBITDA vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's LTM Mar 2026 EBITDA of -$64.18M is the 4th highest of the 10 companies compared; the peer median is -$74.74M.
- Its year-over-year change of -19.1% is the 6th highest of 10, against a peer median of -9.5%.
- EBITDA amounts to 1437.5% of revenue for OCGN, versus a peer median of 291.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $92.9M | +159.9% | — | 939.0% | |
| LTM Mar 2026 | -$17.44M | +88.7% | — | 25.0% | |
| LTM Mar 2026 | -$43.15M | -177.1% | — | 291.9% | |
| LTM Mar 2026 | -$64.18M | -19.1% | — | 1437.5% | |
| LTM Mar 2026 | -$67.05M | -25.2% | — | — | |
| LTM Mar 2026 | -$74.74M | -18129.5% | — | — | |
| LTM Mar 2026 | -$83.2M | +13.7% | — | 105.1% | |
| LTM Mar 2026 | -$95.45M | -22.9% | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$217.64M | +15.4% | — | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$442.87M | -9.5% | — | 5986.3% |
| Peer median (excluding OCGN) | -$74.74M | -9.5% | — | 291.9% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.49M | 6.04M | 4.06M | 4.41M |
| Cost of Revenue | 0 | 0 | 704K | 1.97M | 2.39M |
| Gross Profit | 0 | 2.49M | 5.33M | 2.09M | 2.02M |
| Gross Margin | — | 100.0% | 88.3% | 51.5% | 45.9% |
| Research & Development | 35.11M | 56.16M | 39.57M | 32.13M | 39.75M |
| Selling, General & Admin | 22.92M | 35.4M | 31.99M | 26.69M | 27.58M |
| Operating Expenses | 58.03M | 91.56M | 70.86M | 56.84M | 64.94M |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| EBITDA | (58.11M) | (86.32M) | (62.37M) | (52.09M) | (60.27M) |
| EBITDA Margin | — | -3469.6% | -1033.4% | -1284.5% | -1365.7% |
| Operating Income | (58.03M) | (89.07M) | (65.53M) | (54.76M) | (62.92M) |
| Operating Margin | — | -3580.0% | -1085.7% | -1350.4% | -1425.7% |
| Interest Income | 0 | 1.4M | 2.5M | 1.3M | 922K |
| Interest Expense | 79K | 0 | 0 | 0 | 5.19M |
| Other Income / Expenses | (389K) | 2.27M | 2.45M | 703K | (4.93M) |
| Income Before Tax | (58.42M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Pre-Tax Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| Income Tax Expense | (52K) | 0 | 0 | 0 | 0 |
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Net Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| EPS (Basic) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| EPS (Diluted) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| Weighted Avg Shares | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
| Weighted Avg Shares (Diluted) | 195.01M | 214.6M | 244.33M | 271M | 300.17M |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.